development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for advanced lymphomas and multiple myeloma. It also develops CUDC-427 that has completed Phase I clinical trials for advanced solid tumor and lymphomas; CA-170, which is in preclinical stage for the treatment of cancer; CA-4948, which is in preclinical stage for the treatment of hematologic cancers; Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC); and CUDC-305 drug candidate that has completed Phase I clinical trials for the treatment of cancers. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.